Radiotherapy of brain metastases |
| |
| Authors: | S Egawa I Tukiyama Y Akine Y Kajiura S Yanagawa K Watai K Nomura |
| |
| Affiliation: | 1. Department of Radiation Therapy, Tokyo 104, Japan;2. Department of Neurosurgery, National Cancer Center Hospital, Tsukiji 5 chome, Chuo-ku, Tokyo 104, Japan;3. Department of Radiology, Gifu University School of Medicine, Japan;4. Department of Radiology, Yokohama City University School of Medicine, Japan;1. National Reference Laboratory, Surveillance Laboratory, Swaziland;2. Raleigh Fitkin Memorable Hospital, Swaziland;3. Mbabane Government Hospital, Swaziland;4. Ministry of Health, Expanded Programme for Immunization, Swaziland;5. Swaziland Health Laboratory Services, Swaziland;6. World Health Organization Country Office, Swaziland;7. Centres for Disease Control and Prevention, USA;8. World Health Organization IST ESA, Harare, Zimbabwe;9. World Health Organization Regional Office for Africa, Brazzaville, Congo;1. Department of Radiation Oncology, University Medical Centre Freiburg, Germany;1. Cadence Brain Tumor Center and CDH Proton Center, Warrenville, Illinois;2. University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin;3. Duke University School of Medicine, Durham, North Carolina;4. University of Maryland School of Medicine, Baltimore, Maryland;6. Radiation Therapy Oncology Group—RTQA, Philadelphia, Pennsylvania;5. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania;1. European Cyberknife Center Munich, Munich, Germany;2. Accuray Incorporated, Sunnyvale, CA, USA;3. University Hospital of Cologne, Department for Stereotaxy and Functional Neurosurgery, Cologne, Germany;1. Radiation Oncology Division, Trillium Health Partners, Mississauga, Ontario, Canada;2. Department of Radiation Oncology, University Hospital Mannheim, Mannheim, Germany;3. Department of Radiation Oncology, Institute Verbeeten, Tilburg, Netherlands;4. Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium;5. Eli Lilly Canada, Ontario, Canada;7. Eli Lilly and Company, Indianapolis, Indiana;11. Eli Lilly and Company, Neuilly-sur-Seine, France;12. Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands |
| |
| Abstract: | The effect of radiotherapy in 254 cases of brain metastases, treated between 1977 and 1984, were studied. The cases included 141 of lung cancer, 28 of mammary cancer, and 85 of other primary sites. The percentages of patients with improvement in clinical symptoms were 8, 39, and 66, respectively. These were groups of patients irradiated with less than 30 Gy, 30 Gy to 50 Gy, and more than 50 Gy. The 50% survival periods from the start of irradiation for the last group were as follows: for radiotherapy only, 4.1 months, radiotherapy and surgery, 4.2 months, radiotherapy and chemotherapy combined, 6.9 months, radiotherapy, surgery and chemotherapy combined, 12.1 months. The intervals between the initial diagnosis and brain metastases were different in lung cancer and mammary cancer, but the prognosis after brain metastases showed little difference between them. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
